

Additionalfile1:Table1 Before excluding the patients with M1, clinicopathological characteristics of patients with HAS and Non-HAS treated with radical gastrectomy.

Factors	Before propensity matching		
	Non-HAS n=722 No.(%)	HAS N=75 No.(%)	P value
Sex(M/F)	517/205	61/14	0.072
Age (yr)			0.785
<45	81(11.2%)	7(9.3%)	
60>age≥45	282(39.1%)	32(42.7%)	
≥60	359(49.7%)	36(48.0%)	
Location			0.762
U	217(30.1%)	25(33.3%)	
M	130(18.0%)	9(12%)	
L	365(50.6%)	41(54.7%)	
T	10(1.4%)	0(0.0%)	
Surgery type			0.170
PG	9(1.2%)	2(2.7%)	
DG	354(49.0%)	41 (54.7%)	
TG	356(49.3%)	32 (42.7%)	
TGC	3(0.4%)	0 (0.0%)	

Vascular invasion			0.272
no	327 (45.3%)	292 (38.7%)	
yes	395 (54.7%)	46(61.3%)	
T			0.001
Tis,T0, T1,T2	171(23.7%)	21 (28.0%)	
T3	263 (36.4%)	40 (53.3%)	
T4	288 (39.9%)	14 (18.7%)	
N			0.229
N0	221 (30.6%)	11(14.7%)	
N1	155 (21.5%)	24(32.0%)	
N2	146 (20.2%)	23 (30.7%)	
N3	200 (27.7%)	17 (22.7%)	
M			0.791
M0	711 (98.5%)	73 (97.3%)	
M1	11 (1.5%)	2 (2.7%)	
EGFR			<0.001
-	64 (8.9%)	2 (2.7%)	
+	269 (37.3%)	7 (9.3%)	
++	196 (27.1%)	37 (49.3%)	
+++	193 (26.7%)	29 (38.7%)	

Ki-67			0.003
0-25%	67 (9.3%)	5 (6.7%)	
26-50%	169 (23.4%)	6 (8.0%)	
51-75%	212 (29.4%)	25 (33.3%)	
76-100%	274 (38.0%)	39 (52.05%)	
CEA (ng/ml)			<0.001
≤5	582 (80.6%)	45 (60.0%)	
>5	140(19.4%)	30 (40.0%)	
CA199 (u/ml)			0.022
≤37	614 (85.0%)	71 (94.7%)	
>37	108 (15%)	4 (5.3%)	
Her-2			0.010
-/+	541 (74.9%)	44 (58.7%)	
+++	55 (7.6%)	10 (13.3%)	
++	126 (17.5%)	21 (28.0%)	
neoadjuvant chemotherapy			0.003
no			
yes	637 (88.2%)	57 (76.0%)	
	85 (11.8%)	18 (24.0%)	
